Amphetamine-like effect of l-deprenyl (selegiline) in drug discrimination studies

Sevil Yasar, Jack Bergman

Research output: Contribution to journalArticle

Abstract

l-Deprenyl has dose-dependent amphetamine- and methamphetamine-like discriminative stimulus properties in rats and monkeys. However, these actions occur only at doses that are well above the clinically relevant dose range for l-deprenyl and are likely to reflect its metabolic conversion to amphetamine products. In view of its weak potency for producing amphetamine-like effects and their slow onset, it may not be surprising that l-deprenyl does not appear to have amphetamine-like abuse potential and has been used therapeutically in the treatment of Parkinson syndrome for more than 20 years with no reported instances of abuse.

Original languageEnglish (US)
Pages (from-to)768-773
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume56
Issue number6
StatePublished - Dec 1994

Fingerprint

Selegiline
Amphetamine
Amphetamine-Related Disorders
Pharmaceutical Preparations
Methamphetamine
Haplorhini
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Amphetamine-like effect of l-deprenyl (selegiline) in drug discrimination studies. / Yasar, Sevil; Bergman, Jack.

In: Clinical Pharmacology and Therapeutics, Vol. 56, No. 6, 12.1994, p. 768-773.

Research output: Contribution to journalArticle

@article{60578fd82b2f4613bebc4daed4341a63,
title = "Amphetamine-like effect of l-deprenyl (selegiline) in drug discrimination studies",
abstract = "l-Deprenyl has dose-dependent amphetamine- and methamphetamine-like discriminative stimulus properties in rats and monkeys. However, these actions occur only at doses that are well above the clinically relevant dose range for l-deprenyl and are likely to reflect its metabolic conversion to amphetamine products. In view of its weak potency for producing amphetamine-like effects and their slow onset, it may not be surprising that l-deprenyl does not appear to have amphetamine-like abuse potential and has been used therapeutically in the treatment of Parkinson syndrome for more than 20 years with no reported instances of abuse.",
author = "Sevil Yasar and Jack Bergman",
year = "1994",
month = "12",
language = "English (US)",
volume = "56",
pages = "768--773",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Amphetamine-like effect of l-deprenyl (selegiline) in drug discrimination studies

AU - Yasar, Sevil

AU - Bergman, Jack

PY - 1994/12

Y1 - 1994/12

N2 - l-Deprenyl has dose-dependent amphetamine- and methamphetamine-like discriminative stimulus properties in rats and monkeys. However, these actions occur only at doses that are well above the clinically relevant dose range for l-deprenyl and are likely to reflect its metabolic conversion to amphetamine products. In view of its weak potency for producing amphetamine-like effects and their slow onset, it may not be surprising that l-deprenyl does not appear to have amphetamine-like abuse potential and has been used therapeutically in the treatment of Parkinson syndrome for more than 20 years with no reported instances of abuse.

AB - l-Deprenyl has dose-dependent amphetamine- and methamphetamine-like discriminative stimulus properties in rats and monkeys. However, these actions occur only at doses that are well above the clinically relevant dose range for l-deprenyl and are likely to reflect its metabolic conversion to amphetamine products. In view of its weak potency for producing amphetamine-like effects and their slow onset, it may not be surprising that l-deprenyl does not appear to have amphetamine-like abuse potential and has been used therapeutically in the treatment of Parkinson syndrome for more than 20 years with no reported instances of abuse.

UR - http://www.scopus.com/inward/record.url?scp=0028593637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028593637&partnerID=8YFLogxK

M3 - Article

C2 - 7995019

AN - SCOPUS:0028593637

VL - 56

SP - 768

EP - 773

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -